Research and Markets: U.S. Physician and Payer Perspectives on Emerging Immunomodulators in Psoriasis
Research and Markets (http://www.researchandmarkets.com/research/xbk47q/u_s_physician) has announced the addition of Decision Resources, Inc's new report "U.S. Physician and Payer Perspectives on Emerging Immunomodulators in Psoriasis" to their offering.
The psoriasis market has become lucrative owing to dermatologists' comfort and familiarity with prescribing biologics to patients with moderate to severe disease. The dominance of the tumor necrosis factor-alpha (TNF-a) inhibitors, primarily Amgen/Pfizer/Stiefel/Takeda's Enbrel and Abbott/Eisai's Humira, is being challenged by the interleukin-12 and 23 (IL-12/23) inhibitor Stelara (Janssen Biotech/Janssen-Cilag). Further intensifying the future competitive landscape, two agents in late-stage trials for psoriasis offer the advantage of oral formulationPfizer's Jak-3 inhibitor tasocitinib (CP-690550) and Celgene's phosphodiesterase-4 (PDE-4) inhibitor apremilast.
In addition, topical drugs with novel mechanisms of action (e.g., Incyte's Jak-2 inhibitor ruxolitinib [INCB-18424], Anacor's AN-2728) are set to enter the psoriasis market over the next three years. However, the competitiveness of these agents and their likely positioning in the current treatment algorithm for psoriasis will be strongly impacted by cost as well as physician and payer perceptions of their risk-benefit profiles.
Key Topics Covered:
Executive Summary Slides
Commercial Context Slides
Analysis of Survey Results Slides
About the Author Slide
For Further Information Slide
For more information visit http://www.researchandmarkets.com/research/xbk47q/u_s_physician
Source: Decision Resources, Inc